Monitor for potential strategic shifts in governance or operational focus given the influx of new board members with deep healthcare leadership experience. However, no immediate financial or operational changes are indicated.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $5.45entry
- T+1 · 8mo ago −3.12%α −3.87% · $5.28
- T+5 · 7mo ago −3.30%α −7.25% · $5.27
- T+20 · 7mo ago +8.81%α −0.62% · $5.93
- T+60 · 5mo ago +53.95%α +41.56% · $8.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teladoc Health appointed Susan Salka, former CEO of AMN Healthcare, to its board of directors, effective immediately. This follows recent board changes including the retirement of two directors and the addition of Michael Smith. The move enhances board expertise in healthcare operations and governance.
Key Facts
- Susan Salka appointed to Teladoc Health board of directors effective immediately
- Salka is former president and CEO of AMN Healthcare, where revenue grew to over $5 billion under her leadership
- She will serve on the audit and compensation committees
- Appointment follows retirements of Eric Evans and Thomas McKinley and the addition of Michael Smith
- Salka also serves on the board of Parexel and previously served on boards of McKesson, Beckman Coulter, and Playtex Products
Financial Impact
No direct financial impact disclosed
Risk Factors
- Board refreshment may signal underlying strategic uncertainty or pressure for performance improvement
- No new financial or operational guidance provided with this announcement
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3265043 |
Track record
24 reports on TDOC
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +2.52% at T+1 after the Oct 28, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.60 Now $8.70 +1.22% settles Nov 17
- Nov 6, 202610d ago 144 Neutral 3/10 Entry $8.77 to $8.98 Now $8.70 −0.80% ▲ +2.39% +0.03% vs SPY
- Nov 3, 202613d ago 3 / PRESS-RELEASE Neutral 2/10 Entry $9.70 to $9.41 Now $8.70 −10.31% ▼ −2.99% +1.42% vs SPY
- Nov 3, 202614d ago PTAB Trial Neutral 3/10 Entry $8.89 to $9.70 Now $8.70 −2.14% ▲ +9.11% +7.46% vs SPY
- Oct 28, 202619d ago Press Release Bearish 6/10 No price data
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $8.73 to $8.51 Now $8.70 +0.34% ▲ +2.52% +0.75% vs SPY
- Oct 28, 202620d ago PTAB Trial Neutral 3/10 Entry $8.73 to $8.51 Now $8.70 −0.34% ▼ −2.52% −0.75% vs SPY
- Oct 8, 20265w ago SC 13G Neutral 3/10 Entry $5.54 to $5.77 Now $8.70 +57.04% ▲ +4.15% +3.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.09 to $5.89 Now $8.70 +42.86% ▼ −3.28% −2.54% vs SPY
- Sep 11, 20269w ago 144 Neutral 2/10 Entry $6.16 to $6.50 Now $8.70 +41.23% ▲ +5.52% +5.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers